Cargando…

The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients

We present the AI-discovered aetiology of COVID-19, based on a precise disease model of COVID-19 built under five weeks that best matches the epidemiological characteristics, transmission dynamics, clinical features, and biological properties of COVID-19 and consistently explains the rapidly expandi...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Demiurge Technologies AG. Published by Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428675/ https://www.ncbi.nlm.nih.gov/pubmed/33254502 http://dx.doi.org/10.1016/j.mehy.2020.110180

Ejemplares similares

Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients
por: M, Montero-Baladía, et al.
Publicado: (2020)

Rationale for combined therapies in severe-to-critical COVID-19 patients
por: Gonzaga, Aitor, et al.
Publicado: (2023)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

Etoposide-based therapy for severe forms of COVID-19
por: Hamizi, Kamel, et al.
Publicado: (2020)

The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences
por: Ruiz-Rodríguez, Juan Carlos, et al.
Publicado: (2021)

Nutritional therapy in Covid-19 critically ill patients
por: Castro, M., et al.
Publicado: (2020)

Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids
por: Aoyagi, Tetsuji, et al.
Publicado: (2021)

A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
por: Segar, Jennifer M., et al.
Publicado: (2019)

Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19
por: Takami, Akiyoshi
Publicado: (2020)

Adjuvant corticosteroid therapy for critically ill patients with COVID-19
por: Lu, Xiaofan, et al.
Publicado: (2020)

Application of extracorporeal therapies in critically ill COVID-19 patients
por: ZHOU, Zhifeng, et al.
Publicado: (2021)

Critically ill COVID-19 patient
por: HALAÇLI, Burçin, et al.
Publicado: (2020)

COVID-19 in the Critically Ill Patient
por: Bell, Taison D.
Publicado: (2022)

Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence-
por: Godino, Cosmo, et al.
Publicado: (2021)

Outcomes of renal replacement therapy in the critically ill with COVID-19
por: Burke, E., et al.
Publicado: (2021)

Outcomes of renal replacement therapy in the critically ill with COVID-19
por: Burke, E., et al.
Publicado: (2021)

Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations
por: Gaibani, Paolo, et al.
Publicado: (2021)

Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia
por: Sakr, Yasser, et al.
Publicado: (2021)

Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients
por: Bhandari, Sudhir, et al.
Publicado: (2021)

Perspective from anesthesiologists on the therapy of critically ill patients with COVID-19
por: Li, Hui, et al.
Publicado: (2023)

COVID-19 critical illness in pregnancy
por: Lapinsky, Stephen E, et al.
Publicado: (2021)

Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial
por: Shi, Yuankai, et al.
Publicado: (2015)

Transport of critically ill COVID-19 patients
por: Yousuf, Beena, et al.
Publicado: (2020)

Metoprolol in Critically Ill Patients With COVID-19
por: Clemente-Moragón, Agustín, et al.
Publicado: (2021)

BAROTRAUMA IN CRITICALLY ILL PATIENTS WITH COVID-19
por: MURAG, SOUMYA, et al.
Publicado: (2021)

Caring for the Critically Ill Patient with COVID-19
por: Hensley, Matthew K., et al.
Publicado: (2022)

COVID-19 in the Critically Ill Pregnant Patient
por: Levitus, Matthew, et al.
Publicado: (2022)

The Ætiology of Mental Illness
por: de Villiers, J. J.
Publicado: (1950)

Kidney involvement in COVID-19 and rationale for extracorporeal therapies
por: Ronco, Claudio, et al.
Publicado: (2020)

AI Techniques for COVID-19
Publicado: (2020)

Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies
por: Bikdeli, Behnood, et al.
Publicado: (2020)

The impact of COVID-19 on cervicofacial infection of dental aetiology
por: Politi, I., et al.
Publicado: (2020)

The incidence of venous thromboembolism in critically ill patients with COVID-19 compared with critically ill non-COVID patients
por: Boyd, Sean, et al.
Publicado: (2021)

CONVALESCENT PLASMA THERAPY IN CRITICALLY ILL PATIENTS WITH LATE STAGE COVID-19
por: Kumar, Neil, et al.
Publicado: (2020)

Copper as a potential adjunct therapy for critically ill COVID-19 patients
por: Fooladi, Shahnaz, et al.
Publicado: (2020)

Different barriers to nutritional therapy among critically-ill patients with COVID-19
por: Aguila, Enrik John T., et al.
Publicado: (2021)

Clinical observation of glucocorticoid therapy for critically ill patients with COVID-19 pneumonia
por: Zhu, Yingjie, et al.
Publicado: (2023)

Secondary infections in critically ill patients with COVID-19 receiving steroid therapy
por: Pearce, Alex K, et al.
Publicado: (2023)

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
por: Sekine, I, et al.
Publicado: (2003)

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
por: Goto, K, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_lupea83dcikbbpp6i4mnqe8okt